Please login to the form below

Not currently logged in
Email:
Password:

fezolinetant

This page shows the latest fezolinetant news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas is paying 500m upfront and up to 300m extra in clinical and regulatory milestones for Ogeda (formerly known as Euroscreen) and its lead candidate fezolinetant, which has been shown in ... In a phase IIa trial reported in January, fezolinetant

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    The lead product is a NK3 receptor antagonist (fezolinetant) for treatment of menopause-related vasomotor symptoms (hot flashes).  Fezolinetant successfully completed a phase 2a study in January in 80 menopausal ... regulatory outcomes of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics